# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.
Piper Sandler analyst Biren Amin initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral rating and annou...
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 p...
Rapid reduction in disease activity seen at 12 weeks was sustained at one year55% of patients showed zero C3c staining intensit...
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price t...